BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35596831)

  • 1. Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology.
    Lipman SA; Zhang L; Shah KK; Attema AE
    Eur J Health Econ; 2023 Mar; 24(2):293-305. PubMed ID: 35596831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self vs. other, child vs. adult. An experimental comparison of valuation perspectives for valuation of EQ-5D-Y-3L health states.
    Lipman SA; Reckers-Droog VT; Karimi M; Jakubczyk M; Attema AE
    Eur J Health Econ; 2021 Dec; 22(9):1507-1518. PubMed ID: 34611793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of duration and time preference on the gap between adult and child health state valuations in time trade-off.
    Lang Z; Attema AE; Lipman SA
    Eur J Health Econ; 2024 Jun; 25(4):601-613. PubMed ID: 37420133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using Time Trade-Off Values to Estimate EQ-5D-Y Value Sets: An Exploratory Study.
    Yang Z; Jiang J; Wang P; Wu J; Fang Y; Feng D; Xi X; Luo N
    Value Health; 2023 Jul; 26(7):968-973. PubMed ID: 36921897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective.
    Kreimeier S; Oppe M; Ramos-Goñi JM; Cole A; Devlin N; Herdman M; Mulhern B; Shah KK; Stolk E; Rivero-Arias O; Greiner W
    Value Health; 2018 Nov; 21(11):1291-1298. PubMed ID: 30442276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value Set for the EQ-5D-Y-3L in Hungary.
    Rencz F; Ruzsa G; Bató A; Yang Z; Finch AP; Brodszky V
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):205-215. PubMed ID: 36123448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expect Nothing: The (Lack of) Influence of Subjective Life Expectancy on Valuation of Child Health States.
    Lipman SA
    Front Health Serv; 2022; 2():803109. PubMed ID: 36925864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How different are composite and traditional TTO valuations of severe EQ-5D-5L states?
    Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA
    Qual Life Res; 2016 Aug; 25(8):2101-8. PubMed ID: 26875190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study.
    Ludwig K; von der Schulenburg JG; Greiner W
    Health Qual Life Outcomes; 2017 Feb; 15(1):39. PubMed ID: 28219389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing 2 Alternative Time Trade-Off Methods for Valuation of Children's Health States.
    Yang Z; Devlin NJ; Rand K; Luo N
    Value Health; 2024 Jan; 27(1):43-50. PubMed ID: 37813195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values.
    Fitriana TS; Roudijk B; Purba FD; Busschbach JJV; Stolk E
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):157-167. PubMed ID: 36348155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating an EQ-5D-Y-3L Value Set for China.
    Yang Z; Jiang J; Wang P; Jin X; Wu J; Fang Y; Feng D; Xi X; Li S; Jing M; Zheng B; Huang W; Luo N
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):147-155. PubMed ID: 36396878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modifying the Composite Time Trade-Off Method to Improve Its Discriminatory Power.
    Jakubczyk M; Lipman SA; Roudijk B; Norman R; Pullenayegum E; Yang Y; Gu NY; Stolk E
    Value Health; 2023 Feb; 26(2):280-291. PubMed ID: 36244905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EQ-5D-Y Value Set for Germany.
    Kreimeier S; Mott D; Ludwig K; Greiner W;
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):217-229. PubMed ID: 35604633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In a Child's Shoes: Composite Time Trade-Off Valuations for EQ-5D-Y-3L with Different Proxy Perspectives.
    Lipman SA; Essers BAB; Finch AP; Sajjad A; Stalmeier PFM; Roudijk B
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):181-192. PubMed ID: 36255560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment-Based Valuation Studies Affect Health Preferences?
    Ramos-Goñi JM; Estévez-Carrillo A; Rivero-Arias O; Rowen D; Mott D; Shah K; Oppe M
    Value Health; 2022 Jul; 25(7):1196-1204. PubMed ID: 35379562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing heuristic valuation processes between health state valuation from child and adult perspectives.
    Lipman SA; Reckers-Droog VT
    Eur J Health Econ; 2024 Feb; ():. PubMed ID: 38308719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Think of the Children: A Discussion of the Rationale for and Implications of the Perspective Used for EQ-5D-Y Health State Valuation.
    Lipman SA; Reckers-Droog VT; Kreimeier S
    Value Health; 2021 Jul; 24(7):976-982. PubMed ID: 34243841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values.
    Shah KK; Ramos-Goñi JM; Kreimeier S; Devlin NJ
    Eur J Health Econ; 2020 Sep; 21(7):1091-1103. PubMed ID: 32506281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
    Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
    Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.